Related Experiment Video
Updated: Jul 5, 2026
13:00
Engineering Antiviral Agents via Surface Plasmon Resonance
Published on: June 14, 2022
Update on glycoprotein IIb/IIa inhibitors
V Subbarao1, J Phillips, G A Stouffer
1University of Texas Medical Branch, Galveston, Texas 77555-1064, USA.
Idrugs : the Investigational Drugs Journal
|May 10, 2008
Summary
Glycoprotein IIb/IIIa inhibitors are effective for high-risk procedures and certain heart conditions. Bleeding risks are manageable with experience and careful heparin use, with future research focusing on agent differences and oral formulations.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Glycoprotein IIb/IIIa inhibitors are crucial antiplatelet agents.
- They are used in high-risk percutaneous coronary interventions and acute coronary syndromes like unstable angina and non-Q-wave myocardial infarction.
Purpose of the Study:
- To review the efficacy and safety of Glycoprotein IIb/IIIa inhibitors.
- To discuss the evolution of their clinical application and future research directions.
Main Methods:
- Review of clinical studies and experience with Glycoprotein IIb/IIIa inhibitors.
- Analysis of bleeding complication rates and management strategies.
Main Results:
- Glycoprotein IIb/IIIa inhibitors demonstrate significant benefit in high-risk interventional cardiology and acute coronary syndromes.
- Bleeding complications, initially high, have decreased with clinical experience and optimized heparin dosing.
Conclusions:
- Glycoprotein IIb/IIIa inhibitors remain vital in managing specific cardiovascular conditions.
- Ongoing research will clarify inter-agent differences and the potential of oral formulations for improved patient care.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:25Inhibitors Of Virion Release
Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...